Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Champions Oncology Inc (CSBR)
NASDAQ:CSBR
Holding CSBR?
Track your performance easily
CSBR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.60 - $10.90
Previous CloseN/A
Volume27.06K
Average Volume (3M)79.19K
Market Cap
$137.50M
Enterprise Value$59.12M
Total Cash (Recent Filing)$3.29M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Mar 18, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding13,819,236
10 Day Avg. Volume59,809
30 Day Avg. Volume79,192
Standard Deviation0.17
R-Squared0.00717
Alpha0.00871
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.57
Price to Cash Flow (P/CF)-121.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue1.10
Enterprise Value/Gross Profit2.85
Enterprise Value/Ebitda53.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
Champions Oncology News
PremiumCompany Announcements
Champions Oncology Posts Strong Quarterly Revenue Growth
PremiumCompany Announcements
Champions Oncology Announces Sudden Loss of President
Options Prices
Currently, No data available
---
Ownership Overview
14.27% Insiders
3.01% Mutual Funds
35.11% Other Institutional Investors
45.28% Public Companies and
Individual Investors
CSBR FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was $3.60 and its highest was $10.90 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is $137.50M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Mar 18, 2025 which is in 59 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Dec 11, 2024. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.04.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Overvalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate is -0.01.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,819,236 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of $0.05 in its last earnings report, beating expectations of $0.01. Following the earnings report the stock price went down -11.644%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in CSBR
---
Champions Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
CSBR Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.63%
12-Months-Change
Fundamentals
Return on Equity
-154.52%
Trailing 12-Months
Asset Growth
-10.79%
Trailing 12-Months
Company Description
Champions Oncology Inc
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
---
CSBR Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, positive financial results, improved margins, and a solid cash position. However, there are concerns about potential revenue and cost volatility and a challenging funding environment. Overall, the sentiment is positive with strong confidence in future growth.Read More>---
CSBR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Fulcrum Therapeutics
―
Organovo Holdings
―
Cellectar Biosciences
―
Atossa Therapeutics
―
Best Analysts Covering CSBR
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+21.22%
reiterated a buy rating last month
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +21.22% per trade.
---